Whittier Trust’s VYNE Therapeutics VYNE Stock Holding History

Whittier Trust’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-10	Closed	-$3K	–	1617
2019 Q3	$3K	Buy	+10	New	+$3.23K	﹤0.01%	1339

Other funds holding VYNE

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Whittier Trust's VYNE Position: Q4 2019 in Review

Whittier Trust sold out of VYNE Therapeutics (VYNE) in Q4 2019, closing a stake of 10 shares — an estimated $3K sold.

Whittier Trust first reported a position in VYNE in Q3 2019 and held it in 1 quarter. The position peaked at $3K in Q3 2019. 54 funds tracked by Wall St. Rank hold VYNE as of Q4 2019.

Whittier Trust reported no remaining VYNE Therapeutics position as of Q4 2019 after selling out during the quarter.
Whittier Trust sold 10 VYNE Therapeutics shares in Q4 2019, an estimated $3K.
Whittier Trust first reported a position in VYNE Therapeutics in Q3 2019 and held it in 1 quarter.
Whittier Trust's VYNE Therapeutics position peaked at $3K in Q3 2019.
54 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2019.

Based on Whittier Trust's 13F filing for Q4 2019, filed 31 Jan 2020.